Current trends in immunosuppression.
González Posada
J M
JM
Servicio de Nefrología, Hospital Universitario de Canarias, Ofra s/n. La Laguna, Sta. Cruz de Tenerife. jmgposada@hotmail.com
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D004198:Disease Susceptibility; D006084:Graft Rejection / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods / Q000639:trends*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus